Y-mAbs Therapeutics jumps after Q3 revenue tops estimates

Y-mAbs Therapeutics

08/11/2022 17:25

** Shares of Y-mAbs Therapeutics Inc  YMAB.O  rise ~19% to
$3.98
    ** Stock will see its best day in nearly six months, if
gains hold
    ** Late on Monday, co reported Q3 revenue that beat
analysts' estimates, helped by strong sales of its cancer drug
Danyelza - Refinitiv data 
    ** Also reported smaller-than-expected quarterly net loss of
63 cents/shr, compared with estimates of 71 cents/shr
    ** Including session's move, stock down ~75% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))